Circulating interleukin-18: A specific biomarker for atherosclerosis-prone patients with metabolic syndrome

Nutrition and Metabolism

Volumn 8, Issue , 2011, Pages

  Yamaoka Tojo, Minako ^a   Tojo, Taiki ^a   Wakaume, Kazuki ^a   Kameda, Ryo ^a   Nemoto, Shinji ^a   Takahira, Naonobu ^a   Masuda, Takashi ^a   Izumi, Tohru ^a  

^a KITASATO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; INTERLEUKIN 18;

ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE; BODY WEIGHT; CARDIOVASCULAR SYSTEM; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; HUMAN; INTRAABDOMINAL FAT; LIFESTYLE MODIFICATION; LIPID STORAGE; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; PROTEIN BLOOD LEVEL; STATISTICAL SIGNIFICANCE; WAIST CIRCUMFERENCE; WEIGHT CHANGE; WEIGHT REDUCTION;

EID: 78651532398     PISSN: None     EISSN: 17437075     Source Type: Journal    
DOI: 10.1186/1743-7075-8-3     Document Type: Article

References (50)

1. Grundy SM: Metabolic syndrome pandemic. Arteriosclerosis, thrombosis, and vascular biology 2008, 28(4):629-636.
2. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI, Donato KA, Fruchart JC, James WP, Loria CM, Smith SC Jr: Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation 2009, 120(16):1640-1645.
3. Cornier MA, Dabelea D, Hernandez TL, Lindstrom RC, Steig AJ, Stob NR, Van Pelt RE, Wang H, Eckel RH: The metabolic syndrome. Endocrine reviews 2008, 29(7):777-822.
4. Lakka HM, Laaksonen DE, Lakka TA, Niskanen LK, Kumpusalo E, Tuomilehto J, Salonen JT: The metabolic syndrome and total and cardiovascular disease mortality in middle-aged men. Jama 2002, 288(21):2709-2716. (Pubitemid 35403784)
5. Reaven GM, Lithell H, Landsberg L: Hypertension and associated metabolic abnormalities-the role of insulin resistance and the sympathoadrenal system. The New England journal of medicine 1996, 334(6):374-381. (Pubitemid 26049592)
6. Wang TJ, Larson MG, Keyes MJ, Levy D, Benjamin EJ, Vasan RS: Association of plasma natriuretic peptide levels with metabolic risk factors in ambulatory individuals. Circulation 2007, 115(11):1345-1353. (Pubitemid 46648370)
7. Austin MA, Edwards KL: Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes. Current opinion in lipidology 1996, 7(3):167-171. (Pubitemid 26234230)
8. Coutinho Tde A, Turner ST, Peyser PA, Bielak LF, Sheedy PF, Kullo IJ: Associations of serum uric acid with markers of inflammation, metabolic syndrome, and subclinical coronary atherosclerosis. American journal of hypertension 2007, 20(1):83-89. (Pubitemid 46014067)
9. Servais A, Giral P, Bernard M, Bruckert E, Deray G, Isnard Bagnis C: Is serum cystatin-C a reliable marker for metabolic syndrome? The American journal of medicine 2008, 121(5):426-432.
10. Saleem U, Khaleghi M, Morgenthaler NG, Bergmann A, Struck J, Mosley TH Jr, Kullo IJ: Plasma carboxy-terminal provasopressin (copeptin): a novel marker of insulin resistance and metabolic syndrome. The Journal of clinical endocrinology and metabolism 2009, 94(7):2558-2564.
11. Troseid M, Seljeflot I, Arnesen H: The role of interleukin-18 in the metabolic syndrome. Cardiovascular diabetology 9(1):11.
12. Van Guilder GP, Hoetzer GL, Greiner JJ, Stauffer BL, Desouza CA: Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity (Silver Spring, Md) 2006, 14(12):2127-2131. (Pubitemid 46121966)
13. Zirlik A, Abdullah SM, Gerdes N, MacFarlane L, Schonbeck U, Khera A, McGuire DK, Vega GL, Grundy S, Libby P, et al: Interleukin-18, the metabolic syndrome, and subclinical atherosclerosis: results from the Dallas Heart Study. Arteriosclerosis, thrombosis, and vascular biology 2007, 27(9):2043-2049. (Pubitemid 47312316)
14. Blankenberg S, Luc G, Ducimetiere P, Arveiler D, Ferrieres J, Amouyel P, Evans A, Cambien F, Tiret L: Interleukin-18 and the risk of coronary heart disease in European men: the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation 2003, 108(20):2453-2459. (Pubitemid 37444405)
15. Everett BM, Bansal S, Rifai N, Buring JE, Ridker PM: Interleukin-18 and the risk of future cardiovascular disease among initially healthy women. Atherosclerosis 2009, 202(1):282-288.
16. Skurk T, Kolb H, Muller-Scholze S, Rohrig K, Hauner H, Herder C: The proatherogenic cytokine interleukin-18 is secreted by human adipocytes. European journal of endocrinology/European Federation of Endocrine Societies 2005, 152(6):863-868. (Pubitemid 40903576)
17. Fain JN, Tichansky DS, Madan AK: Most of the interleukin 1 receptor antagonist, cathepsin S, macrophage migration inhibitory factor, nerve growth factor, and interleukin 18 release by explants of human adipose tissue is by the non-fat cells, not by the adipocytes. Metabolism: clinical and experimental 2006, 55(8):1113-1121.
18. Kadoglou NP, Iliadis F, Angelopoulou N, Perrea D, Ampatzidis G, Liapis CD, Alevizos M: The anti-inflammatory effects of exercise training in patients with type 2 diabetes mellitus. Eur J Cardiovasc Prev Rehabil 2007, 14(6):837-843. (Pubitemid 350197015)
19. Kadoglou NP, Iliadis F, Sailer N, Athanasiadou Z, Vitta I, Kapelouzou A, Karayannacos PE, Liapis CD, Alevizos M, Angelopoulou N, et al: Exercise training ameliorates the effects of rosiglitazone on traditional and novel cardiovascular risk factors in patients with type 2 diabetes mellitus. Metabolism: clinical and experimental 59(4):599-607.
20. Xu H, Barnes GT, Yang Q, Tan G, Yang D, Chou CJ, Sole J, Nichols A, Ross JS, Tartaglia LA, et al: Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. The Journal of clinical investigation 2003, 112(12):1821-1830. (Pubitemid 38063705)
21. Jung C, Gerdes N, Fritzenwanger M, Figulla HR: Circulating levels of interleukin-1 family cytokines in overweight adolescents. Mediators of inflammation 2010, 958403.
22. Okamura H, Tsutsi H, Komatsu T, Yutsudo M, Hakura A, Tanimoto T, Torigoe K, Okura T, Nukada Y, Hattori K, et al: Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature 1995, 378(6552):88-91.
23. Parnet P, Garka KE, Bonnert TP, Dower SK, Sims JE: IL-1Rrp is a novel receptor-like molecule similar to the type I interleukin-1 receptor and its homologues T1/ST2 and IL-1R AcP. The Journal of biological chemistry 1996, 271(8):3967-3970. (Pubitemid 26074141)
24. Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, Tedgui A: Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation 2001, 104(14):1598-1603. (Pubitemid 32947520)
25. Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, Humbert Y, Chvatchko Y, Tedgui A: Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circulation research 2001, 89(7):E41-45.
26. Pomerantz BJ, Reznikov LL, Harken AH, Dinarello CA: Inhibition of caspase 1 reduces human myocardial ischemic dysfunction via inhibition of IL-18 and IL-1beta. Proceedings of the National Academy of Sciences of the United States of America 2001, 98(5):2871-2876. (Pubitemid 32209576)
27. Netea MG, Joosten LA, Lewis E, Jensen DR, Voshol PJ, Kullberg BJ, Tack CJ, van Krieken H, Kim SH, Stalenhoef AF, et al: Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nature medicine 2006, 12(6):650-656. (Pubitemid 43865233)
28. Fischer CP, Perstrup LB, Berntsen A, Eskildsen P, Pedersen BK: Elevated plasma interleukin-18 is a marker of insulin-resistance in type 2 diabetic and non-diabetic humans. Clinical immunology (Orlando, Fla) 2005, 117(2):152-160. (Pubitemid 41407725)
29. Aso Y, Okumura K, Takebayashi K, Wakabayashi S, Inukai T: Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intimal-media wall thickness in patients with type 2 diabetes. Diabetes care 2003, 26(9):2622-2627. (Pubitemid 37052110)
30. Hung J, McQuillan BM, Chapman CM, Thompson PL, Beilby JP: Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arteriosclerosis, thrombosis, and vascular biology 2005, 25(6):1268-1273. (Pubitemid 40776620)
31. Zilverschoon GR, Tack CJ, Joosten LA, Kullberg BJ, van der Meer JW, Netea MG: Interleukin-18 resistance in patients with obesity and type 2 diabetes mellitus. International journal of obesity (2005) 2008, 32(9):1407-1414.
32. Tiret L, Godefroy T, Lubos E, Nicaud V, Tregouet DA, Barbaux S, Schnabel R, Bickel C, Espinola-Klein C, Poirier O, et al: Genetic analysis of the interleukin-18 system highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation 2005, 112(5):643-650. (Pubitemid 41099042)
33. He M, Cornelis MC, Kraft P, van Dam RM, Sun Q, Laurie CC, Mirel DB, Chasman DI, Ridker PM, Hunter DJ, et al: Genome-wide association study identifies variants at the IL18-BCO2 locus associated with interleukin-18 levels. Arteriosclerosis, thrombosis, and vascular biology 30(4):885-890.
34. Presta I, Andreozzi F, Succurro E, Marini MA, Laratta E, Lauro R, Hribal ML, Perticone F, Sesti G: IL-18 gene polymorphism and metabolic syndrome. Nutr Metab Cardiovasc Dis 2009, 19(2):e5-6.
35. Yamaoka-Tojo M, Tojo T, Masuda T, Machida Y, Kitano Y, Kurosawa T, Izumi T: C-reactive protein-induced production of interleukin-18 in human endothelial cells: a mechanism of orchestrating cytokine cascade in acute coronary syndrome. Heart and vessels 2003, 18(4):183-187. (Pubitemid 37258671)
36. Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht HJ: Interleukin-18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation 2002, 106(1):24-30. (Pubitemid 34747437)
37. Espinola-Klein C, Rupprecht HJ, Bickel C, Lackner K, Genth-Zotz S, Post F, Munzel T, Blankenberg S: Impact of inflammatory markers on cardiovascular mortality in patients with metabolic syndrome. Eur J Cardiovasc Prev Rehabil 2008, 15(3):278-284.
38. Troseid M, Seljeflot I, Hjerkinn EM, Arnesen H: Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: synergistic effect of inflammation and hyperglycemia. Diabetes care 2009, 32(3):486-492.
39. Yamagami H, Kitagawa K, Hoshi T, Furukado S, Hougaku H, Nagai Y, Hori M: Associations of serum IL-18 levels with carotid intima-media thickness. Arteriosclerosis, thrombosis, and vascular biology 2005, 25(7):1458-1462. (Pubitemid 40923368)
40. Troseid M, Seljeflot I, Weiss TW, Klemsdal TO, Hjerkinn EM, Arnesen H: Arterial stiffness is independently associated with interleukin-18 and components of the metabolic syndrome. Atherosclerosis 209(2):337-339.
41. Chapman CM, McQuillan BM, Beilby JP, Thompson PL, Hung J: Interleukin-18 levels are not associated with subclinical carotid atherosclerosis in a community population. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Atherosclerosis 2006, 189(2):414-419.
42. Nakamura A, Shikata K, Hiramatsu M, Nakatou T, Kitamura T, Wada J, Itoshima T, Makino H: Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes care 2005, 28(12):2890-2895. (Pubitemid 43942920)
43. Esposito K, Pontillo A, Ciotola M, Di Palo C, Grella E, Nicoletti G, Giugliano D: Weight loss reduces interleukin-18 levels in obese women. The Journal of clinical endocrinology and metabolism 2002, 87(8):3864-3866. (Pubitemid 34879540)
44. Troseid M, Arnesen H, Hjerkinn EM, Seljeflot I: Serum levels of interleukin- 18 are reduced by diet and n-3 fatty acid intervention in elderly high-risk men. Metabolism: clinical and experimental 2009, 58(11):1543-1549.
45. Esposito K, Pontillo A, Di Palo C, Giugliano G, Masella M, Marfella R, Giugliano D: Effect of weight loss and lifestyle changes on vascular inflammatory markers in obese women: a randomized trial. Jama 2003, 289(14):1799-1804. (Pubitemid 37430249)
46. Bruun JM, Stallknecht B, Helge JW, Richelsen B: Interleukin-18 in plasma and adipose tissue: effects of obesity, insulin resistance, and weight loss. European journal of endocrinology/European Federation of Endocrine Societies 2007, 157(4):465-471. (Pubitemid 350018450)
47. Lindegaard B, Hansen T, Hvid T, van Hall G, Plomgaard P, Ditlevsen S, Gerstoft J, Pedersen BK: The effect of strength and endurance training on insulin sensitivity and fat distribution in human immunodeficiency virus-infected patients with lipodystrophy. The Journal of clinical endocrinology and metabolism 2008, 93(10):3860-3869.
48. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985, 28(7):412-419. (Pubitemid 15018832)
49. Arai H, Yamamoto A, Matsuzawa Y, Saito Y, Yamada N, Oikawa S, Mabuchi H, Teramoto T, Sasaki J, Nakaya N, et al: Prevalence of metabolic syndrome in the general Japanese population in 2000. Journal of atherosclerosis and thrombosis 2006, 13(4):202-208.
50. Yamaoka-Tojo M, Tojo T, Inomata T, Machida Y, Osada K, Izumi T: Circulating levels of interleukin 18 reflect etiologies of heart failure: Th1/Th2 cytokine imbalance exaggerates the pathophysiology of advanced heart failure. Journal of cardiac failure 2002, 8(1):21-27. (Pubitemid 34163846)